Welcome to our dedicated page for Ocular Therapeut SEC filings (Ticker: OCUL), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Ocular Therapeutix, Inc. (NASDAQ: OCUL) SEC filings page on Stock Titan provides direct access to the company’s regulatory disclosures, including 8-K current reports and other documents filed with the U.S. Securities and Exchange Commission. These filings give detailed insight into Ocular Therapeutix’s clinical programs, financing activities, and key corporate events as it advances ophthalmic therapies based on its ELUTYX bioresorbable hydrogel technology.
Recent 8-K filings describe the structure and status of the AXPAXLI (OTX-TKI) registrational trials in wet age-related macular degeneration (wet AMD), including the SOL-1 and SOL-R Phase 3 studies, as well as plans for the SOL-X long-term extension trial. They also outline the design of the HELIOS-2 and HELIOS-3 Phase 3 trials in non-proliferative diabetic retinopathy (NPDR), the use of a novel ordinal diabetic retinopathy severity score (DRSS) endpoint, and Special Protocol Assessment (SPA) agreements with the FDA.
Other filings cover capital markets transactions, such as the September 30, 2025 underwriting agreement for a large common stock offering, expected net proceeds, and the company’s view of its cash runway into future years. Additional 8-Ks furnish quarterly financial results press releases, describe inducement equity awards under Nasdaq Listing Rule 5635(c)(4), and discuss notices of allowance from the U.S. Patent and Trademark Office related to AXPAXLI methods of use.
On Stock Titan, these SEC filings are updated in near real time from EDGAR and can be paired with AI-powered summaries that explain the key points of lengthy documents like 8-Ks or registration statements in plain language. Users can quickly see how Ocular Therapeutix reports on trial designs, primary endpoints, regulatory interactions, cash resources, and potential patent protection. For investors tracking OCUL, this page is a central place to review official disclosures about clinical progress, financing arrangements, and other material events that may influence the company’s ophthalmology-focused pipeline and commercial product DEXTENZA.
Ocular Therapeutix, Inc. is making investor presentation slides available covering detailed results from its SOL-1 Phase 3 superiority clinical trial of AXPAXLI (also known as OTX-TKI) for treating wet age-related macular degeneration. The slides will be posted on the company’s website Investors section on February 27, 2026, aligned with its presentation at the 49th Macula Society Annual Meeting.
Ocular Therapeutix director and officer Pravin Dugel reported an automatic sale of 20,056 shares of common stock at a weighted average price of $8.28 per share. According to the disclosure, the transaction was carried out under a durable automatic sale instruction adopted on February 21, 2024 to cover tax withholding obligations tied to restricted stock units vesting on February 22, 2026, and is described as not being a discretionary trade.
After this open-market sale, Dugel directly holds 3,013,022 common shares, and an additional 300,115 shares are reported as held indirectly through the Pravin Dugel 2024 Irrevocable Trust.
Ocular Therapeutix Chief Development Officer Peter Kaiser reported an open-market sale of 2,810 shares of common stock at a weighted average price of $8.28 per share. The shares were sold under a durable automatic sale instruction to cover tax withholding from restricted stock units vesting on February 22, 2026. After this transaction, he directly owns 269,108 shares.
Ocular Therapeutix, Inc.’s Chief Scientific Officer Jeffrey S. Heier reported an automatic sale of 3,057 shares of common stock. The shares were sold in an open-market transaction at a weighted average price of $8.28 per share to cover tax withholding tied to restricted stock units that vested on February 22, 2026.
The transaction was executed under a durable automatic sale instruction adopted on April 9, 2024, meaning it was not a discretionary trade. After this sale, Heier directly held 323,368 shares of Ocular Therapeutix common stock.
Ocular Therapeutix Chief Strategy Officer Sanjay Nayak reported an automatic sale of 1,759 shares of common stock. The shares were sold in an open-market transaction at a weighted average price of $8.28 per share under a pre-arranged durable automatic sale instruction.
The sale was made to cover tax withholding obligations tied to the vesting of restricted stock units on February 22, 2026, and is described as non-discretionary. After this sell-to-cover transaction, Nayak directly held 330,653 shares of Ocular Therapeutix common stock.
Ocular Therapeutix, Inc.’s Chief Medical Officer, Nadia Waheed, reported an open‑market sale of 3,510 shares of common stock at a weighted average price of $7.74 per share on February 20, 2026. The sale was executed under a durable automatic sale instruction adopted on June 1, 2024 to cover tax withholding from restricted stock units that vested on February 11, 2026, and is described as non‑discretionary. Following this transaction, Waheed beneficially owns 314,907 shares of Ocular Therapeutix common stock.
Ocular Therapeutix director Richard L. Lindstrom, MD, bought shares of the company’s common stock in the open market. On this transaction date, he purchased 60,229 shares at a weighted average price of $7.66 per share, bringing his directly held stake to 246,933 shares.
OCUL submitted a notice to sell 2,810 shares of common stock tied to restricted stock vesting under a registered plan, dated 02/22/2026.
Shares outstanding were 217,691,779 as of 02/23/2026. The excerpt also shows a prior sale of 3,007 common shares on 11/24/2025 for
Oculus Therapeutics (OCUL) reported proposed sales of common stock via a Form 144 notice tied to restricted shares vesting under a registered plan on
The filing names Pravin Dugel and lists prior sales of 124,882 shares on
Morgan Stanley Smith Barney LLC Executive Financial Services submitted a notice regarding the proposed sale of 3,057 common shares tied to restricted stock vesting under a registered plan, dated 02/22/2026. The filing lists that the sale method is by the Issuer.
The excerpt also shows a prior sale by Jeffrey S. Heier of 3,469 common shares on 11/24/2025, with a numeric value 41,771.96 recorded alongside that transaction.